UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006802
Receipt number R000007984
Scientific Title Clinical study for monitoring of therapy effect on breast cancer using 18F-fluoromisonidazole PET/CT
Date of disclosure of the study information 2011/12/01
Last modified on 2019/04/01 12:43:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study for monitoring of therapy effect on breast cancer using 18F-fluoromisonidazole PET/CT

Acronym

Monitoring of therapy effect on breast cancer using 18F-FMISO PET/CT

Scientific Title

Clinical study for monitoring of therapy effect on breast cancer using 18F-fluoromisonidazole PET/CT

Scientific Title:Acronym

Monitoring of therapy effect on breast cancer using 18F-FMISO PET/CT

Region

Japan


Condition

Condition

breast cancer

Classification by specialty

Breast surgery Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

An aim of this study is to monitor the therapy effect on breast cancer using FMISO PET/CT.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Relation between the shrinkage and the FMISO uptake in the breast cancer after 2-4 cycles of chemotherapy and after completion of therapy.

Key secondary outcomes

Relation between the prognosis and the FMISO uptake in the breast cancer after 2-4 cycles of chemotherapy and after completion of therapy.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

PET/CT imaging 2 hrs after administration of F-18-fluoromisonidazole (FMISO) ( 7.4MBq/kg ) at 3 time points of pretherapy, 2-4 cycles after chemotherapy and posttherapy ( presurgery ).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with breast cancer who are eligible for surgical treatment.
2) Patients with breast cancer who are eligible for surgical treatment after presurgical treatment ( chmotherapy and/or hormone therapy ).
3) Patients who are consent to participate in this study

Key exclusion criteria

1) Pregnant female or female having possibility of pregnancy
2) Patients ineligible for participating in this study because of other reasons

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Ichiei
Middle name
Last name Kuji

Organization

Saitama International Medical Center, Saitama Medical University

Division name

Department of Nuclear Medicine

Zip code

350-1298

Address

1397-1 Yamane, Hidaka-shi, Saitama 350-1298

TEL

042-984-4147

Email

kuji@saitama-med.ac.jp


Public contact

Name of contact person

1st name Ichiei
Middle name
Last name Kuji

Organization

Saitama International Medical Center, Saitama Medical University

Division name

Clinical test assistant center

Zip code

350-1298

Address

1397-1 Yamane, Hidaka-shi, Saitama 350-1298

TEL

042-984-4523

Homepage URL

http://www.saitama-med.ac.jp/kokusai/support_center.html

Email

chikens@saitama-med.ac.jp


Sponsor or person

Institute

Saitama Medical University

Institute

Department

Personal name



Funding Source

Organization

Saitama Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Saitama Medical University International Medical Center Crinical trial IRB

Address

1397-1 Yamane, Hidaka-shi, Saitama 350-1298

Tel

042-984-4523

Email

chikens@saitama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

埼玉医科大学国際医療センター


Other administrative information

Date of disclosure of the study information

2011 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

43

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 11 Month 30 Day

Date of IRB

2011 Year 11 Month 09 Day

Anticipated trial start date

2011 Year 12 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 11 Month 30 Day

Last modified on

2019 Year 04 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007984


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name